Join the Oncology Voice Network. Join for Free
KEYS to SUCCESS in small start-ups vs. big pharma
Small Pharma Companies Transitioning to Smaller Firms Field Medical Roles Recruitment Challenges Career Progression in Biotech

KEYS to SUCCESS in small start-ups vs. big pharma


Share This Article


Summary

In this episode, Tom Caravela is joined by Jim Morgan to explore the unique landscape of working in small pharma companies. Jim shares insights from his extensive background in large pharma, highlighting the pros and challenges of transitioning to smaller firms. They discuss the critical role of field medical in companies lacking commercial teams and the recruitment challenges faced by small pharma. The conversation delves into strategic and tactical roles, team dynamics, and career progression within small biotech environments. Jim offers valuable advice for those considering a move to small pharma startups, emphasizing job stability and growth opportunities.

Jim Morgan, National Director, Oncology MSLs, discusses the KEY to success for working in small start ups vs. big pharma.

Jim shares…

πŸ‘‰ Pros and cons for Small vs. Large Pharma

πŸ‘‰ How to overcome lack of infrastructure and support

πŸ‘‰ What its like to navigate in an early stage, pre-commercial environment

πŸ‘‰ How to be both strategic and tactical at the same time

πŸ‘‰ What skills are mandatory for Small Pharma vs Large

Click for Source
Small Pharma Companies, Transitioning to Smaller Firms, Field Medical Roles, Recruitment Challenges, Career Progression in Biotech

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
OVN Avatar A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Podcast
The Ideal Roadmap for New MSLs
Partner Avatar MSL Talk: Tom Caravela, Sarah Snyder

The Ideal Roadmap for New MSLs

Article
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
OVN Avatar B. Gyawali, E. G. E. de Vries, U. Dafni, T. Amaral, J. Barriuso, J. Bogaerts, A. Calles, G. Curigliano, C. Gomez-Roca, B. Kiesewetter, S. Oosting, A. Passaro, G. Pentheroudakis, M. Piccart, F. Roitberg, J. Tabernero, N. Tarazona, D. Trapani, R. Wester, G.

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

Explore OVN